SCHEMBL12640360

SCHEMBL12640360

CC(C)(C)OC(=O)N(Cc1cncc(F)c1)c1ccc(C=O)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC1 Q13547 1/20 0.36
ADORA2B P29275 4/20 0.35
ADORA2A P29274 4/20 0.35
ALDH1A1 P00352 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GRM2 Q14416 1/20 0.33
KDM1A O60341 2/20 0.33
SSTR4 P31391 1/20 0.32
KMT2A Q03164 1/20 0.31
BACE1 P56817 1/20 0.31
BACE2 Q9Y5Z0 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
SLC6A4 P31645 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
POLB P06746 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2599997 0.86 ADORA2B (0.35) HDAC8HDAC6HDAC1ADORA2BADORA2A
SCHEMBL12675092 0.85 HDAC8 (0.34) HDAC8HDAC6HDAC1ALDH1A1L3MBTL1
SCHEMBL12675293 0.84 ADORA2B (0.38) HDAC8HDAC6HDAC1ADORA2BADORA2A
SCHEMBL12675091 0.84 ADORA2B (0.39) HDAC8HDAC6HDAC1ADORA2BADORA2A
SCHEMBL12675113 0.83 ADORA2B (0.34) HDAC8HDAC6HDAC1ADORA2BADORA2A
SCHEMBL1886731 0.83 TRPM8 (0.33) HDAC8HDAC6HDAC1ALDH1A1L3MBTL1
SCHEMBL12674769 0.82 HDAC8 (0.35) HDAC8HDAC6HDAC1ALDH1A1L3MBTL1
SCHEMBL12640371 0.82 ADORA2B (0.33) HDAC8HDAC6HDAC1ADORA2BADORA2A
SCHEMBL12674780 0.82 ADORA2B (0.38) HDAC8HDAC6HDAC1ADORA2BADORA2A
SCHEMBL1267086 0.81 KDM4E (0.39) HDAC8HDAC6HDAC1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 WO disclosed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF HDAC8 1851/4885HDAC6 2506/4885HDAC1 2665/4885
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF HDAC8 1851/4885HDAC6 2506/4885HDAC1 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.